31st January 2017, Libourne, France - Ceva international teams will use the 2017 International Poultry Expo, the world's largest poultry exhibition to be held in Atlanta, GA, USA, to stress the need of latest technology for better disease control.
Vectormune® ND with ten years of market availability brings the ultimate antivirus solution to reduce ND shedding with maximal protection and no side effect.
Cevac IBird®, Cevac® IBron, Cevac® IBras, is the unique IB variant vaccines range to face Infectious Bronchitis all over the world.
Ceva in 2013 launched Cevac IBird® in Europe, and rapidly made it available in many countries around the world.
This vaccine has demonstrated when it is combined with a Massachusetts vaccine at the hatchery its capacity to protect from multiple IB variant viruses from all over the world (QX, Q1, Malaysian variant, Var2 etc ...)
Recently in the U.S. Ceva research has developed a GA 08 vaccine to answer the needs of U.S. poultry industry to control GA 08 and GA 13 variant viruses. Since last year Cevac® IBron has demonstrated its capacity in field conditions to improve IB control in hatchery application to prevent these IB variant strains.
In 2016, in Brazil Ceva has obtained the registration of Cevac® IBras a unique BR1 IB vaccine that will give to Brazilian poultry industry the first tool to control this widespread virus.
Through its R&D investment and industry commitment Ceva has been able to bring new solutions to address IB problems all over the world.
Ceva remains committed to providing poultry producers with the largest line of vector vaccines registered in the USA, new vaccination equipment and service packages for hatchery and farms.
Ceva will be delighted to welcome you at Booth #C2905 Hall C
>> Download the PDF version: